Comparison of group I and II soluble phospholipases A2 activities on phagocytic functions of human polymorphonuclear and mononuclear phagocytes.
Soluble phospholipase A2 (PLA2) purified from rheumatoid synovial fluid (group II) and repurified Naja naja venom PLA2 (group I) were compared for their influence on phagocytic activity of human polymorphonuclear (PMN) and mononuclear (MO) phagocytes. Group II PLA2 reduced chemotaxis, adhesiveness, and intracellular bactericidal activity (ICBA) and induced release of muramidase from PMNs. Group I PLA2 suppressed chemotaxis, and enhanced ICBA but had no influence on other phagocytic functions. Group II PLA2 purified from synovial fluid or from placenta caused marked spontaneous superoxide generation followed by inhibition of phagocytosis-induced burst of energy. Group I Naja naja and porcine pancreatic PLA2 had no effect on superoxide generation. Group II but not group I PLA2 reduced markedly ICBA of monocytes. It may be concluded that human group II soluble PLA2, in concentrations comparable to those present in inflamed joints or in sera of patients with active arthritis or septic shock, causes spontaneous formation of the oxygen radical superoxide and release of lysosomal enzymes, and suppresses conventional phagocytic activities of PMNs and monocytes. Marked differences between group I and group II PLA2s may mean that these enzymes exert different influences on cell membrane.
Pruzanski
W
W
Inflammation Research Group, Wellesley Hospital, University of Toronto, Canada.
Saito
S
S
Stefanski
E
E
Vadas
P
P
D001172:Arthritis, Rheumatoid / Q000201:enzymology; D001433:Bacteriolysis / Q000187:drug effects; D002448:Cell Adhesion / Q000187:drug effects; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D003864:Depression, Chemical; D004546:Elapid Venoms / Q000032:analysis; D006801:Humans; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism; D009113:Muramidase / Q000378:metabolism; D009504:Neutrophils / Q000187:drug effects* / Q000378:metabolism; D010587:Phagocytosis / Q000187:drug effects*; D010741:Phospholipases A / Q000145:classification / Q000378:metabolism*; D054467:Phospholipases A2; D013481:Superoxides / Q000378:metabolism; D013582:Synovial Fluid / Q000201:enzymology
D004546:Elapid Venoms; D013481:Superoxides; D010741:Phospholipases A; D054467:Phospholipases A2; D009113:Muramidase